271 related articles for article (PubMed ID: 19509135)
21. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy.
Lee YY; Choi CH; Do IG; Song SY; Lee W; Park HS; Song TJ; Kim MK; Kim TJ; Lee JW; Bae DS; Kim BG
Gynecol Oncol; 2011 Aug; 122(2):361-5. PubMed ID: 21570711
[TBL] [Abstract][Full Text] [Related]
22. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
[TBL] [Abstract][Full Text] [Related]
23. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Jaehde U
J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
[TBL] [Abstract][Full Text] [Related]
24. Role of copper transporters in the uptake and efflux of platinum containing drugs.
Safaei R
Cancer Lett; 2006 Mar; 234(1):34-9. PubMed ID: 16297532
[TBL] [Abstract][Full Text] [Related]
25. The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy.
Öhrvik H; Thiele DJ
J Trace Elem Med Biol; 2015; 31():178-82. PubMed ID: 24703712
[TBL] [Abstract][Full Text] [Related]
26. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K
Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422
[TBL] [Abstract][Full Text] [Related]
27. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
Abada PB; Larson CA; Manorek G; Adams P; Howell SB
Mol Pharmacol; 2012 Sep; 82(3):510-20. PubMed ID: 22710939
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
Holzer AK; Katano K; Klomp LW; Howell SB
Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465
[TBL] [Abstract][Full Text] [Related]
29. Transporter-Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level.
Schneider V; Chaib S; Spanier C; Knapp M; Moscvin V; Scordovillo L; Ewertz A; Jaehde U; Kalayda GV
AAPS J; 2017 Nov; 20(1):9. PubMed ID: 29192345
[TBL] [Abstract][Full Text] [Related]
30. Regulation of Cisplatin cytotoxicity by cu influx transporters.
Abada P; Howell SB
Met Based Drugs; 2010; 2010():317581. PubMed ID: 21274436
[TBL] [Abstract][Full Text] [Related]
31. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
Jandial DD; Farshchi-Heydari S; Larson CA; Elliott GI; Wrasidlo WJ; Howell SB
Clin Cancer Res; 2009 Jan; 15(2):553-60. PubMed ID: 19147760
[TBL] [Abstract][Full Text] [Related]
32. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.
Kim ES; Tang X; Peterson DR; Kilari D; Chow CW; Fujimoto J; Kalhor N; Swisher SG; Stewart DJ; Wistuba II; Siddik ZH
Lung Cancer; 2014 Jul; 85(1):88-93. PubMed ID: 24792335
[TBL] [Abstract][Full Text] [Related]
33. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
Jandial DD; Messer K; Farshchi-Heydari S; Pu M; Howell SB
Gynecol Oncol; 2009 Dec; 115(3):362-6. PubMed ID: 19775736
[TBL] [Abstract][Full Text] [Related]
34. Role of copper transporters in resistance to platinating agents.
Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
[TBL] [Abstract][Full Text] [Related]
35. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
36. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
37. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.
Holzer AK; Samimi G; Katano K; Naerdemann W; Lin X; Safaei R; Howell SB
Mol Pharmacol; 2004 Oct; 66(4):817-23. PubMed ID: 15229296
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
[TBL] [Abstract][Full Text] [Related]
39. A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment.
Landon CD; Benjamin SE; Ashcraft KA; Dewhirst MW
Int J Hyperthermia; 2013 Sep; 29(6):528-38. PubMed ID: 23879689
[TBL] [Abstract][Full Text] [Related]
40. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
